Effect of hemodialysis on plasma levels of vascular endothelial markers

被引:8
作者
Naumnik, B [1 ]
Borawski, J [1 ]
Pawlak, K [1 ]
Mysliwiec, M [1 ]
机构
[1] Med Acad, Dept Nephrol & Internal Med, PL-15540 Bialystok, Poland
关键词
arterial blood pressure; endothelium; dialysis membrane; tissue factor pathway inhibitor;
D O I
10.1177/107602960200800308
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Vascular endothelial cell dysfunction is linked to hemostatic abnormalities and accelerated atherosclerosis in patients receiving maintenance hemodialysis (HD). The relationships between pre-dialysis plasma levels of immunoreactive thrombomodulin, von Willebrand factor, tissue factor and its inhibitor were studied, and the effects of HD procedure on these endothelial markers were observed. All the markers were higher in 39 HD patients than in 15 healthy controls (p<0.0001). HD treatment resulted in a 50% increase in tissue factor pathway inhibitor (p<0.0001), but did not influence the other markers. This increment directly correlated with the post-dialysis decrease in diastolic (p=0.011) and mean arterial blood pressure (p=0.039), and the surface area of the dialysis membrane (p=0.007). There were no associations between the increase in tissue factor pathway inhibitor and the amount of fluid removed, dose of enoxaparin, or other HD-specific factors. In conclusion, HD is responsible for an increase in plasma tissue pathway factor inhibitor level. The release of tissue factor pathway inhibitor during HD is not only due to heparin injection but also to the contact between blood and artificial dialysis membrane, and to HD-activated hemodynamic forces.
引用
收藏
页码:245 / 250
页数:6
相关论文
共 22 条
[1]
Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease [J].
Blacher, J ;
Pannier, B ;
Guerin, AP ;
Marchais, SJ ;
Safar, ME ;
London, GM .
HYPERTENSION, 1998, 32 (03) :570-574
[2]
Increased soluble thrombomodulin does not always indicate endothelial injury [J].
Borawski, J ;
Naumnik, B ;
Mysliwiec, M .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2002, 8 (01) :87-89
[3]
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response [J].
Borawski, J ;
Naumnik, B ;
Pawlak, K ;
Mysliwiec, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (07) :1442-1447
[4]
Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients [J].
Borawski, J ;
Naumnik, B ;
Pawlak, K ;
Mysliwiec, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (04) :787-792
[5]
Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis [J].
Cella, G ;
Vertolli, U ;
Naso, A ;
Vianello, A ;
Rampin, E ;
Sbarai, A ;
Boeri, G ;
Strauss, WE .
THROMBOSIS RESEARCH, 1996, 81 (06) :671-677
[6]
Gimbrone MA, 1999, THROMB HAEMOSTASIS, V82, P722
[7]
INCREASED CARDIOVASCULAR RISK-FACTORS AND FEATURES OF ENDOTHELIAL ACTIVATION AND DYSFUNCTION IN DIALYZED UREMIC PATIENTS [J].
GRIS, JC ;
BRANGER, B ;
VECINA, F ;
ALSABADANI, B ;
FOURCADE, J ;
SCHVED, JF .
KIDNEY INTERNATIONAL, 1994, 46 (03) :807-813
[8]
Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): A possible mechanism for difference in therapeutic efficacy [J].
Hansen, JB ;
Sandset, PM .
THROMBOSIS RESEARCH, 1998, 91 (04) :177-181
[9]
KARIO K, 1995, THROMB HAEMOSTASIS, V73, P763
[10]
KARIO K, 1994, THROMB HAEMOSTASIS, V71, P275